| Market Capitalization (Millions $) |
106 |
| Shares
Outstanding (Millions) |
115 |
| Employees |
766 |
| Revenues (TTM) (Millions $) |
304 |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
17 |
| Capital Exp. (TTM) (Millions $) |
0 |
Coherus Biosciences Inc
Coherus Biosciences Inc is a biotechnology company that is focused on the development and commercialization of biosimilar drugs.
Founded in 2010 and headquartered in Redwood City, California, Coherus is dedicated to increasing patient access to high-quality, affordable biologic medicines.
The company has a strong clinical and regulatory team with extensive experience in developing biosimilars and managing complex global development programs.
The company's leading product, UDENYCAe (pegfilgrastim-cbqv), is a biosimilar to Neulastae and is used to reduce the risk of infection in patients undergoing chemotherapy.
UDENYCAe was approved by the U.
S.
Food and Drug Administration (FDA) in November 2018 and has been launched in the United States through a collaboration with partner, Pfizer.
Coherus has also developed its own proprietary product, CHS-1420, a biosimilar to adalimumab (Humirae).
CHS-1420 has completed its Phase 3 clinical trial and is currently awaiting FDA approval.
Coherus has a robust pipeline of other biosimilar candidates targeting leading biologic drugs, such as bevacizumab (Avastine), ranibizumab (Lucentise), and aflibercept (Eyleae).
Coherus is also exploring the development of novel therapies in the areas of immuno-oncology and oncology supportive care.
In addition to its biosimilar development program, Coherus has established a strong intellectual property portfolio and has entered into several key collaborations to optimize the development and commercialization of its products.
The company is focused on maintaining a strong financial position and has raised over $1 billion in funding since its inception.
Overall, Coherus Biosciences Inc is a leading biosimilar company with a strong focus on delivering high-quality, affordable medicines for patients in need.
Company Address: 333 Twin Dolphin Drive Redwood City 94065 CA
Company Phone Number: 649-3530 Stock Exchange / Ticker: NASDAQ CHRS
|
1.35%